Cape Coral
239-208-3000
In 2016, the drugmaker Mylan, now known as Viatris Inc, faced widespread public outrage and condemnation due to a dramatic increase in the price of EpiPen allergy treatments, an auto-injectable device that delivers the drug epinephrine for use when experiencing a life-threatening allergic reaction known as anaphylaxis. That price increase saw a pair of EpiPen treatments soar from $100 in 2008, to $600 in 2016, making it less accessible for the patients who needed it.
On Monday, Viatris Inc (Mylan) agreed to a $264 million settlement to resolve a class action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment. This case, brought on behalf of consumers, health insurance companies, and other third-party payers, was scheduled to go on trial this month with the plaintiffs seeking $1 billion in damages.
This lawsuit accused Mylan and Pfizer of “unlawfully exercising its monopoly power”, or engaging in wide-ranging anticompetitive behavior that allowed them to maintain a monopoly over the market for these devices.
EpiPens are made by two subsidiaries of Pfizer and are sold by Viatris.
Much of the original case against Mylan was dismissed last year, however, by U.S. District Judge Daniel Crabtree in Kansas City, Kansas, leaving only a claim concerning a 2012 patent litigation settlement with generic drug-maker Teva Pharmaceutical Industries Ltd.
Viatris said the settlement, which is pending court approval, does not contain any admission of liability.
The plaintiffs alleged that the defendants entered into an unlawful “pay-for-delay” settlement with Teva which resulted in the delayed released of a generic version of the EpiPen, allowing Mylan to dramatically increase its product's price without fear of a competitive product.
The plaintiffs alleged that Mylan as part of a “quid pro quo” agreed to also settle unrelated patent litigation involving a brand name drug Teva produced and delay the release of Mylan's proposed generic version of said medication.
Teva and Pfizer have denied wrongdoing. Pfizer agreed to a settlement of $345 million last year. Teva was not a defendant.
We’re only a phone call away! Call our Fort Myers or Cape Cod law office now and let us know how we can help.
Fort Myers
Address: 1533 Hendry Street
Suite 200 (Second Floor)
Fort Myers, FL 33901
Fax: 239-461-3915
Cape Coral
239-208-3000
Address: 1625 S.E. 47th Terrace
Suite 1
Cape Coral, FL 33904
Fax: 239-461-3915
Available 24 hours, 7 days a week